Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meglumine antimoniate versus miltefosine for cutaneous leishmaniasis
ACTRN12626000038392Phase 4Active, not recruiting
- Sponsor
- Khyber Teaching Hospital
- Start
- Oct 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of meglumine antimoniate and miltefosine in cutaneous leishmaniasis (CL) (2 arms), sponsored by Khyber Teaching Hospital. Primary endpoint: Comparative efficacy of intramuscular meglumine antimoniate and oral miltefosine in the treatment of cutaneous leishmaniasis. Started Oct 2025; status: active, not recruiting.
02
Drugs
meglumine antimoniatemiltefosine
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on ACTRN12626000038392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000038392.